Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

, AGN

Allergan

$216.81

-4.44 (-2.01%)

15:32
01/11/17
01/11
15:32
01/11/17
15:32

AbbVie promises to keep drug price increases under 10%, Reuters reports

AbbVie (ABBV) CEO Richard Gonzalez promised to keep all drug price increases in 2017 under 10%, following Allergan (AGN) and Novo Nordisk's (NVO) pledge to do the same, according to Reuters. During the annual JPMorgan Healthcare Conference, the executive said his company would raise prices just once this year, with the percentage increases not exceeding single digits, the publication noted. Reference Link

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

AGN

Allergan

$216.81

-4.44 (-2.01%)

NVO

Novo Nordisk

$35.61

-0.4 (-1.11%)

  • 11

    Jan

  • 27

    Jan

  • 01

    Feb

  • 21

    Feb

ABBV AbbVie
$61.27

-2.16 (-3.41%)

12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/21/16
PIPR
12/21/16
NO CHANGE
Target $129
PIPR
Overweight
Vertex well in lead but Galapagos a competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that while Galapagos NV (GLPG) and AbbVie's (ABBV) CFTR potentiator GLPG1837 is " clearly a competitor" following the Phase II SAPHIRA-1 data, Vertex Pharmaceuticals (VRTX) remains "well in the lead." The Phase III KALYDECO plus follow-on VX-661 data is expected in the first half of 2017 while the Phase II triple combination data with VX-440 and VX-152 is expected in the second half of the year, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Vertex with a $129 price target.
01/05/17
JEFF
01/05/17
NO CHANGE
Target $90
JEFF
Buy
Jefferies keeps AbbVie as top global Pharma pick for 2017
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals for 2017. The stock should again outperform as visibility on the timeline for U.S. Humira biosimilars "increases against bearish consensus expectations," Holford tells investors in a research note. He also expects "important advances" on AbbVie's pipeline throughtout the year, and highlights Rova-T, Imbruvica, Venclexta, risankizumab and veliparib. Holford keeps a Buy rating on the shares with a $90 price target.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
AGN Allergan
$216.81

-4.44 (-2.01%)

01/05/17
WELS
01/05/17
NO CHANGE
WELS
Outperform
Allergan 2017 outlook in-line with estimates, says Wells Fargo
Wells Fargo analyst David Maris says Allergan's preliminary outlook for 2017 today was in-line with his and the current expectations. The analyst notes Allergan's outlook does not include accretion from the recently announced acquisition of LifeCell. Maris keeps an Outperform rating on the shares with a $250-$255 price target range.
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.
12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
NVO Novo Nordisk
$35.61

-0.4 (-1.11%)

12/06/16
UBSW
12/06/16
UPGRADE
UBSW
Buy
Novo Nordisk upgraded to Buy from Sell at UBS
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan

TODAY'S FREE FLY STORIES

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
Peters & Co. hold a conference »

Limited Energy Conference…

ETFC

E-Trade

$36.39

0.15 (0.41%)

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
E*Trade to hold education day »

E*Trade's Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

AMGN

Amgen

$154.67

0.87 (0.57%)

, BAYRY

Bayer

$109.31

0.98 (0.90%)

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 Gastrointestinal…

AMGN

Amgen

$154.67

0.87 (0.57%)

BAYRY

Bayer

$109.31

0.98 (0.90%)

BMY

Bristol-Myers

$49.23

-6.26 (-11.28%)

CCXI

ChemoCentryx

$7.56

-0.32 (-4.06%)

CELG

Celgene

$112.66

-0.96 (-0.84%)

DNA

Bought by RHHBY

EXEL

Exelixis

$17.92

0.02 (0.11%)

HALO

Halozyme

$11.50

0.42 (3.79%)

LXRX

Lexicon

$13.84

-0.19 (-1.35%)

MACK

Merrimack

$3.00

-0.05 (-1.64%)

MRK

Merck

$62.53

2.2 (3.65%)

NVS

Novartis

$70.65

0.22 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Jan

  • 26

    Jan

  • 01

    Feb

  • 02

    Feb

  • 12

    Feb

  • 16

    Feb

  • 21

    Feb

  • 23

    Feb

  • 24

    Feb

  • 28

    Feb

  • 02

    Mar

  • 08

    Mar

  • 15

    Mar

  • 10

    May

  • 27

    May

  • 19

    Jul

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

, COH

Coach

$35.31

0.21 (0.60%)

18:54
01/20/17
01/20
18:54
01/20/17
18:54
Periodicals
Kate Spade draws interest from Coach, Michael Kors, Bloomberg reports »

Kate Spade (KATE) is…

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

COH

Coach

$35.31

0.21 (0.60%)

KORS

Michael Kors

$42.46

0.43 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

CTIC

CTI BioPharma

$4.97

-0.1 (-1.97%)

18:14
01/20/17
01/20
18:14
01/20/17
18:14
Hot Stocks
CTI BioPharma regains compliance with Nasdaq Listing Rule »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$40.46

0.06 (0.15%)

18:06
01/20/17
01/20
18:06
01/20/17
18:06
Hot Stocks
Abbott sponsored study shows SCS therapy can reduce, stabilize opioid use »

New research has found…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 21

    Feb

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

18:02
01/20/17
01/20
18:02
01/20/17
18:02
Periodicals
Wal-Mart begins corporate job cuts at headquarters, WSJ reports »

Wal-Mart has started on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$35.31

0.21 (0.60%)

, KORS

Michael Kors

$42.46

0.43 (1.02%)

17:46
01/20/17
01/20
17:46
01/20/17
17:46
Periodicals
Breaking Periodicals news story on Coach, Michael Kors, Kate Spade »

Coach, Michael Kors to…

COH

Coach

$35.31

0.21 (0.60%)

KORS

Michael Kors

$42.46

0.43 (1.02%)

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

BELFB

Bel Fuse

$31.80

0.2 (0.63%)

17:33
01/20/17
01/20
17:33
01/20/17
17:33
Hot Stocks
Gabelli reports 23.15% stake in Bel Fuse »

GAMCO, pursuant to Rule…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$63.65

0.75 (1.19%)

17:32
01/20/17
01/20
17:32
01/20/17
17:32
Hot Stocks
ResMed, BMC, 3B Medical settle global litigation »

ResMed, BMC, and 3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.50

0.05 (1.45%)

17:27
01/20/17
01/20
17:27
01/20/17
17:27
Hot Stocks
Breaking Hot Stocks news story on Northern Oil and Gas »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$4.06

0.01 (0.25%)

17:12
01/20/17
01/20
17:12
01/20/17
17:12
Hot Stocks
Baytex Energy closes Peace River acquisition »

Baytex Energy closed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$25.60

1 (4.07%)

17:09
01/20/17
01/20
17:09
01/20/17
17:09
Hot Stocks
FibroGen 'encouraged' by updated pamrevlumab clinical data »

FibroGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$18.86

-0.199 (-1.04%)

17:03
01/20/17
01/20
17:03
01/20/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Innovative Industrial Properties »

Alan D. Gold raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITE

SiteOne Landscape

$37.26

0.41 (1.11%)

17:03
01/20/17
01/20
17:03
01/20/17
17:03
Hot Stocks
SiteOne Landscape acquires Aspen Valley Landscape Supply »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCB

Itau Corpbanca

$12.55

-0.08 (-0.63%)

17:01
01/20/17
01/20
17:01
01/20/17
17:01
Hot Stocks
Itau Corpbanca files Material Event Notice »

Itau Corpbanca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$232.20

0.79 (0.34%)

16:50
01/20/17
01/20
16:50
01/20/17
16:50
Hot Stocks
Goldman Sachs chief accounting officer Smith to become global head of compliance »

Goldman Sachs said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$6.65

0.1 (1.53%)

16:47
01/20/17
01/20
16:47
01/20/17
16:47
Hot Stocks
DAVIDsTEA announces two leadership departures »

DAVIDsTEA's Chief HR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

, BAYRY

Bayer

$109.31

0.98 (0.90%)

16:47
01/20/17
01/20
16:47
01/20/17
16:47
General news
On The Fly: Stocks end week mixed as Trump takes office »

Stocks ended the week…

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

BAYRY

Bayer

$109.31

0.98 (0.90%)

GM

General Motors

$37.01

-0.29 (-0.78%)

NFLX

Netflix

$138.60

0.19 (0.14%)

XOM

Exxon Mobil

$85.89

1.16 (1.37%)

JCP

J.C. Penney

$6.85

0.16 (2.39%)

NKE

Nike

$53.20

0.27 (0.51%)

CSX

CSX

$44.33

-1.18 (-2.59%)

CP

Canadian Pacific

$150.99

0.68 (0.45%)

FWP

Forward Pharma

$30.76

2.01 (6.99%)

CWEI

Clayton Williams

$146.85

-1.18 (-0.80%)

NBL

Noble Energy

$40.21

-0.06 (-0.15%)

RAI

Reynolds American

$58.71

0.13 (0.22%)

BTI

British American Tobacco

$117.30

0.54 (0.46%)

LLY

Eli Lilly

$76.81

-0.03 (-0.04%)

CLCD

CoLucid Pharmaceuticals

$46.25

-0.05 (-0.11%)

WBA

Walgreens Boots Alliance

$81.72

-1.77 (-2.12%)

RAD

Rite Aid

$7.46

-1.14 (-13.26%)

TGT

Target

$64.10

-1.29 (-1.97%)

GIMO

Gigamon

$34.20

1.35 (4.11%)

PSO

Pearson

FAST

Fastenal

$51.24

0.69 (1.37%)

CHKP

Check Point

$97.79

1.45 (1.51%)

PG

Procter & Gamble

$87.45

2.75 (3.25%)

IBM

IBM

$170.55

3.74 (2.24%)

SWKS

Skyworks

$88.67

10.21 (13.01%)

MS

Morgan Stanley

$42.59

0.14 (0.33%)

PRGS

Progress Software

$28.18

0.16 (0.57%)

CMA

Comerica

$66.96

0.65 (0.98%)

UNH

UnitedHealth

$158.66

-0.04 (-0.03%)

GS

Goldman Sachs

$232.20

0.79 (0.34%)

C

Citi

$56.11

-0.55 (-0.97%)

RCII

Rent-A-Center

$8.40

0.09 (1.08%)

GE

General Electric

$30.53

-0.68 (-2.18%)

AXP

American Express

$76.20

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 20

    Jan

  • 24

    Jan

  • 26

    Jan

  • 26

    Jan

  • 31

    Jan

  • 02

    Feb

  • 07

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 19

    Apr

TSO

Tesoro

$80.48

-0.08 (-0.10%)

16:42
01/20/17
01/20
16:42
01/20/17
16:42
Hot Stocks
Breaking Hot Stocks news story on Tesoro »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$42.59

0.14 (0.33%)

, OIBR

Oi S.A.

16:40
01/20/17
01/20
16:40
01/20/17
16:40
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Oi S.A.  »

Morgan Stanley reports 5%…

MS

Morgan Stanley

$42.59

0.14 (0.33%)

OIBR

Oi S.A.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMH

UMH Properties

16:36
01/20/17
01/20
16:36
01/20/17
16:36
Hot Stocks
UMH Properties closes acquisition of two Ohio communities for about $9.6M »

UMH Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOP

Bioptix

$3.43

0.01 (0.29%)

16:36
01/20/17
01/20
16:36
01/20/17
16:36
Hot Stocks
Bioptix announces workforce reductions »

Bioptix adopted a plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$115.60

0.02 (0.02%)

16:35
01/20/17
01/20
16:35
01/20/17
16:35
Hot Stocks
Court rejects attempt to enforce Ecuadorian judgment against Chevron unit »

A Canadian court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 23

    Mar

MIME

Mimecast

$21.42

-0.95 (-4.25%)

16:34
01/20/17
01/20
16:34
01/20/17
16:34
Syndicate
Breaking Syndicate news story on Mimecast »

Mimecast files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

  • 13

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.